BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 28575060)

  • 1. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
    Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
    PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimony susceptible
    Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
    Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
    Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
    Kulshrestha A; Bhandari V; Mukhopadhyay R; Ramesh V; Sundar S; Maes L; Dujardin JC; Roy S; Salotra P
    Parasitol Res; 2013 Feb; 112(2):825-8. PubMed ID: 23239091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
    Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
    Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
    Hendrickx S; Van Bockstal L; Bulté D; Mondelaers A; Aslan H; Rivas L; Maes L; Caljon G
    Parasit Vectors; 2020 Feb; 13(1):96. PubMed ID: 32087758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
    Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
    Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.
    Verma A; Bhandari V; Deep DK; Sundar S; Dujardin JC; Singh R; Salotra P
    Int J Parasitol Drugs Drug Resist; 2017 Dec; 7(3):370-377. PubMed ID: 29035735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.
    Khanra S; Sarraf NR; Das AK; Roy S; Manna M
    Sci Rep; 2017 Sep; 7(1):10330. PubMed ID: 28871097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.
    Vanaerschot M; De Doncker S; Rijal S; Maes L; Dujardin JC; Decuypere S
    PLoS One; 2011; 6(8):e23120. PubMed ID: 21829701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterization.
    Shaw CD; Lonchamp J; Downing T; Imamura H; Freeman TM; Cotton JA; Sanders M; Blackburn G; Dujardin JC; Rijal S; Khanal B; Illingworth CJ; Coombs GH; Carter KC
    Mol Microbiol; 2016 Mar; 99(6):1134-48. PubMed ID: 26713880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death.
    Mishra J; Singh S
    Exp Parasitol; 2013 Oct; 135(2):397-406. PubMed ID: 23968687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
    Prajapati VK; Sharma S; Rai M; Ostyn B; Salotra P; Vanaerschot M; Dujardin JC; Sundar S
    Am J Trop Med Hyg; 2013 Oct; 89(4):750-4. PubMed ID: 23980130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.
    Hendrickx S; Boulet G; Mondelaers A; Dujardin JC; Rijal S; Lachaud L; Cos P; Delputte P; Maes L
    Parasitol Res; 2014 May; 113(5):1875-81. PubMed ID: 24615359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
    Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India.
    Mandal S; Maharjan M; Singh S; Chatterjee M; Madhubala R
    J Antimicrob Chemother; 2010 Mar; 65(3):496-507. PubMed ID: 20067981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.
    Mishra J; Madhubala R; Singh S
    Parasitol Res; 2013 Mar; 112(3):1001-9. PubMed ID: 23242321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
    Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
    J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.